The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
CAMBRIDGE UNIV PRESS
Autores
SPINAZZOLA, Edoardo
QUATTRONE, Diego
RODRIGUEZ, Victoria
TROTTA, Giulia
ALAMEDA, Luis
TRIPOLI, Giada
GAYER-ANDERSON, Charlotte
FREEMAN, Tom P.
JOHNSON, Emma C.
JONGSMA, Hannah E.
Citação
PSYCHOLOGICAL MEDICINE, v.53, n.15, p.7418-7427, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BackgroundWhile cannabis use is a well-established risk factor for psychosis, little is known about any association between reasons for first using cannabis (RFUC) and later patterns of use and risk of psychosis. MethodsWe used data from 11 sites of the multicentre European Gene-Environment Interaction (EU-GEI) case-control study. 558 first-episode psychosis patients (FEPp) and 567 population controls who had used cannabis and reported their RFUC.We ran logistic regressions to examine whether RFUC were associated with first-episode psychosis (FEP) case-control status. Path analysis then examined the relationship between RFUC, subsequent patterns of cannabis use, and case-control status. ResultsControls (86.1%) and FEPp (75.63%) were most likely to report 'because of friends' as their most common RFUC. However, 20.1% of FEPp compared to 5.8% of controls reported: 'to feel better' as their RFUC (chi(2) = 50.97; p < 0.001). RFUC 'to feel better' was associated with being a FEPp (OR 1.74; 95% CI 1.03-2.95) while RFUC 'with friends' was associated with being a control (OR 0.56; 95% CI 0.37-0.83). The path model indicated an association between RFUC 'to feel better' with heavy cannabis use and with FEPp-control status. ConclusionsBoth FEPp and controls usually started using cannabis with their friends, but more patients than controls had begun to use 'to feel better'. People who reported their reason for first using cannabis to 'feel better' were more likely to progress to heavy use and develop a psychotic disorder than those reporting 'because of friends'.
Palavras-chave
Cannabis use, path analysis, psychotic disorders
URI
https://observatorio.fm.usp.br/handle/OPI/58969
Referências
  1. Arseneault L, 2002, BRIT MED J, V325, P1212, DOI 10.1136/bmj.325.7374.1212
  2. Barkus EJ, 2006, PSYCHOPATHOLOGY, V39, P175, DOI 10.1159/000092678
  3. Bianconi F, 2016, PSYCHOL MED, V46, P995, DOI 10.1017/S0033291715002494
  4. Buchan BJ, 2002, ADDICTION, V97, P98, DOI 10.1046/j.1360-0443.97.s01.1.x
  5. Dekker N, 2010, PSYCHOL MED, V40, P1325, DOI 10.1017/S0033291709991814
  6. Dekker N, 2009, PSYCHOPATHOLOGY, V42, P350, DOI 10.1159/000236906
  7. Dekker N, 2012, INT J METH PSYCH RES, V21, P286, DOI 10.1002/mpr.1362
  8. Di Forti M, 2019, LANCET PSYCHIAT, V6, P427, DOI 10.1016/S2215-0366(19)30048-3
  9. Di Forti M, 2015, LANCET PSYCHIAT, V2, P233, DOI 10.1016/S2215-0366(14)00117-5
  10. Di Forti M, 2009, BRIT J PSYCHIAT, V195, P488, DOI 10.1192/bjp.bp.109.064220
  11. Dragt S, 2010, CAN J PSYCHIAT, V55, P165, DOI 10.1177/070674371005500308
  12. Etain B, 2017, J PSYCHIATR RES, V84, P73, DOI 10.1016/j.jpsychires.2016.09.022
  13. Ferdinand RF, 2005, ADDICTION, V100, P612, DOI 10.1111/j.1360-0443.2005.01070.x
  14. Ferraro L, 2021, SCHIZOPHR RES, V236, P69, DOI 10.1016/j.schres.2021.08.008
  15. Ferraro L, 2020, SCHIZOPHRENIA BULL, V46, P517, DOI 10.1093/schbul/sbz077
  16. Ferraro L, 2013, SCHIZOPHR RES, V150, P129, DOI 10.1016/j.schres.2013.07.046
  17. Freeman TP, 2021, ADDICTION, V116, P1000, DOI 10.1111/add.15253
  18. Freeman TP, 2014, ADDICTION, V109, P1686, DOI 10.1111/add.12634
  19. Gayer-Anderson C, 2020, SOC PSYCH PSYCH EPID, V55, P645, DOI 10.1007/s00127-020-01831-x
  20. Gobbi G, 2019, JAMA PSYCHIAT, V76, P426, DOI 10.1001/jamapsychiatry.2018.4500
  21. Pérez LG, 2014, ACTAS ESP PSIQUIATRI, V42, P83
  22. Green B, 2004, DRUG ALCOHOL REV, V23, P445, DOI 10.1080/09595230412331324563
  23. Hjorthoj C, 2021, JAMA PSYCHIAT, V78, P1013, DOI 10.1001/jamapsychiatry.2021.1471
  24. Hjorthoj C, 2021, PSYCHOL MED, V51, P617, DOI 10.1017/S0033291719003532
  25. Jongsma HE, 2018, JAMA PSYCHIAT, V75, P36, DOI 10.1001/jamapsychiatry.2017.3554
  26. KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259
  27. Kolliakou A, 2011, INT J DEV NEUROSCI, V29, P335, DOI 10.1016/j.ijdevneu.2010.11.006
  28. Korver N, 2010, AUST NZ J PSYCHIAT, V44, P230, DOI 10.3109/00048670903487118
  29. Kwok OM, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01936
  30. Leung J, 2022, PSYCHOPHARMACOLOGY, V239, P1509, DOI 10.1007/s00213-021-06047-8
  31. Mallett R, 2002, SOC PSYCH PSYCH EPID, V37, P329, DOI 10.1007/s00127-002-0557-4
  32. Marconi A, 2016, SCHIZOPHRENIA BULL, V42, P1262, DOI 10.1093/schbul/sbw003
  33. Martin AJ, 2011, EDUC PSYCHOL REV, V23, P235, DOI 10.1007/s10648-011-9160-0
  34. Maxwell ME, 1992, Family Interview for Genetic Studies
  35. MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764
  36. Murray RM, 2017, NEUROPHARMACOLOGY, V124, P89, DOI 10.1016/j.neuropharm.2017.06.018
  37. Mustonen A, 2018, BRIT J PSYCHIAT, V212, P227, DOI 10.1192/bjp.2017.52
  38. Peters BD, 2009, AUST NZ J PSYCHIAT, V43, P1155, DOI 10.3109/00048670903179095
  39. Radhakrishnan R, 2023, PSYCHOL MED, V53, P5551, DOI 10.1017/S0033291722002756
  40. Radhakrishnan Rajiv, 2014, Front Psychiatry, V5, P54, DOI 10.3389/fpsyt.2014.00054
  41. Stage FK, 2004, J EDUC RES, V98, P5, DOI 10.3200/JOER.98.1.5-13
  42. Tripoli G, 2021, PSYCHOL MED, V51, P623, DOI 10.1017/S003329171900357X
  43. van Os J, 2021, SCHIZOPHRENIA BULL, V47, P594, DOI 10.1093/schbul/sbab019
  44. Williams J, 1996, PSYCHOL MED, V26, P775, DOI 10.1017/S003329170003779X

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPR